|Dr. Jan-Anders Karlsson||CEO & Exec. Director||N/A||N/A||1955|
|Mr. Piers John Morgan||Chief Financial Officer||N/A||N/A||1966|
|Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA||Gen. Counsel||N/A||N/A||1967|
|Ms. Victoria Stewart||Director of Communications||N/A||N/A||N/A|
|Dr. Peter Spargo||Sr. VP of Chemistry Manufacturing & Controls||N/A||N/A||1962|
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Verona Pharma plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.